Pharvaris’s Oral HAE Prevention Data May Threaten BioCryst’s Orladeyo

The Swiss firm reported that its oral bradykinin B2 receptor antagonist reduced monthly hereditary angioedema attacks by 84.5% compared with placebo, suggesting biologic-like efficacy with an oral drug.